Skip to main content
Toggle navigation
Login
Search
Home
Tweets by ASCPT 2022 Annual Meeting
Pharmacometrics & Pharmacokinetics (PMK)
Home
Pharmacometrics & Pharmacokinetics (PMK)
Pharmacometrics & Pharmacokinetics (PMK)
Type here to filter the list
P-002 - VIRAL KINETIC MECHANISTIC MODELING OF THE FIRST-IN-CLASS ONCOLYTIC VIRUS THERAPY TALIMOGENE LAHERPAREPVEC (TVEC) IN SUBJECTS WITH ADVANCED MELANOMA.
Favorite
P-008 - BEMPEDOIC ACID (BA) PHYSIOLOGICALLY-BASED PHARMACOKINETIC (PBPK) MODEL TO ASSESS THE BIOEQUIVALENCE (BE) OF BA ORAL SUSPENSION AND COMMERCIAL IMMEDIATE RELEASE (IR) TABLET FORMULATIONS IN A VIRTUAL POPULATION OF HEALTHY ADULTS.
Favorite
P-010 - DEVELOPMENT OF A KINETIC-PHARMACODYNAMIC MODEL TO GUIDE FIRST IN HUMAN DOSE SELECTION FOR mRNA-6231, AN INVESTIGATIONAL mRNA THERAPEUTIC ENCODING A LONG-ACTING SELECTIVE IL-2 TO PREFERENTIALLY EXPAND REGULATORY T CELLS.
Favorite
P-011 - IN VITRO TO IN VIVO EXTRAPOLATION OF CLEARANCE TO PREDICT STEREOSELECTIVE DISPOSITION OF BUPROPION.
Favorite
P-012 - STEREOSELECTIVE METABOLISM OF BUPROPION IN CELLULAR FRACTION OF HUMAN LIVER AND INTESTINE.
Favorite
P-018 - ALTERNATIVES TO RIFAMPICIN: PERSPECTIVE ON THE CHOICE OF STRONG CYP3A INDUCERS FOR CONDUCTING CLINICAL DRUG-DRUG INTERACTION STUDIES.
Favorite
P-019 - PHARMACOKINETIC MODELING OF EP547 AND SIMULATIONS OF EXPOSURE IN HEPATIC IMPAIRMENT.
Favorite
P-029 - POPULATION PHARMACOKINETIC ANALYSIS OF ALDAFERMIN.
Favorite
P-034 - POPULATION PK MODELING OF BUSULFAN IN ADULT PATIENTS RECEIVING FLUBU4 AND ALLOGENEIC HEMATOPOIETIC STEM CELL TRANSPLANTATION (HSCT).
Favorite
P-035 - ITEM RESPONSE THEORY MODELING FRAMEWORK FOR EVALUATING MIGRAINE-SPECIFIC QUESTIONNAIRE (MSQ) IN MIGRAINE DRUG DEVELOPMENT.
Favorite
P-036 - POPULATION PHARMACOKINETIC ANALYSIS OF SPARSENTAN IN HEALTHY VOLUNTEERS AND SUBJECTS WITH FOCAL SEGMENTAL GLOMERULOSCLEROSIS (FSGS).
Favorite
P-037 - BMS-986256, AN ORAL NOVEL TOLL-LIKE RECEPTOR 7 AND 8 (TLR7/8) INHIBITOR, IS NOT A SENSITIVE SUBSTRATE OF CYTOCHROME P450 3A4: CLINICAL EVALUATION WITH ITRACONAZOLE.
Favorite
P-043 - LONGITUDINAL PHARMACODYNAMIC (PD) MODELS TO INVESTIGATE EFFICACY AND OCULAR SAFETY FOLLOWING BELANTAMAB MAFODOTIN (BELAMAF) ADMINISTRATION IN PATIENTS WITH RELAPSED/REFRACTORY MULTIPLE MYELOMA (RRMM).
Favorite
P-045 - EXPOSURE-RESPONSE (ER) RELATIONSHIP BETWEEN LORLATINIB (LOR) PLASMA EXPOSURE AND INCREASE IN BLOOD PRESSURE (BP) IN PATIENTS (PTS) WITH ADVANCED ANAPLASTIC LYMPHOMA KINASE (ALK) POSITIVE NON-SMALL CELL LUNG CANCER (NSCLC).
Favorite
P-047 -
WITHDRAWN
- MODEL INFORMED DEVELOPMENT OF LRRK2 INHIBITOR DNL201 IN PARKINSON’S DISEASE: A POPPK-PD APPROACH FOR DOSE SELECTION WITH A SUSTAINED RELEASE (SR) FORMULATION.
Favorite
P-050 - APPLICATION OF LONG SHORT-TERM MEMORY RECURRENT NEURAL NETWORK IN POPULATION PHARMACOKINETIC MODELING.
Favorite
P-054 - PHYSIOLOGICALLY-BASED PHARMACOKINETIC MODELING OF OAT1/3 ACTIVITY IN PATIENTS WITH CHRONIC KIDNEY DISEASE.
Favorite
P-055 - PRIORITIZING DRUGS AS A FIRST STEP TOWARDS EFFICIENT USE OF EXISTING PBPK MODELS TO IMPROVE PEDIATRIC DOSING GUIDELINES.
Favorite
P-063 - AN OPEN-LABEL, SINGLE-DOSE STUDY OF THE PHARMACOKINETICS AND SAFETY OF INFIGRATINIB (BGJ398) IN SUBJECTS WITH MODERATE RENAL IMPAIRMENT AND IN MATCHED HEALTHY ADULTS.
Favorite
P-065 - A PHASE 1 SINGLE ASCENDING DOSE (SAD) STUDY OF INCB054707, A JAK1 INHIBITOR, IN HEALTHY PARTICIPANTS.
Favorite
P-066 - A PHASE 1 MULTIPLE ASCENDING DOSE (MAD) STUDY OF INCB054707, A JAK1 INHIBITOR, IN HEALTHY PARTICIPANTS.
Favorite
P-069 - PHYSIOLOGICALLY-BASED PHARMACOKINETIC (PBPK) MODEL TO CHARACTERIZE ORGAN DISTRIBUTION OF BACTERIOPHAGE (PHAGE) IN PRECLINICAL MOUSE STUDIES.
Favorite
P-070 - RENAL FUNCTION ESTIMATION EQUATIONS IN PEDIATRICS: IMPLICATIONS ON VANCOMYCIN EXPOSURE.
Favorite
P-079 - PHARMACOKINETICS, SAFETY, AND TOLERABILITY OF INHALED REMDESIVIR IN HEALTHY SUBJECTS.
Favorite
P-080 - PHYSIOLOGICALLY BASED PHARMACOKINETICS MODELING OF RIBOCICLIB IN PEDIATRIC PATIENTS WITH CANCER.
Favorite
P-081 - EXTERNAL VALIDATION OF A TUMOR GROWTH INHIBITION-OVERALL SURVIVAL MODEL IN NON-SMALL-CELL LUNG CANCER BASED ON ATEZOLIZUMAB STUDIES USING ALECTINIB DATA.
Favorite
P-082 - A DDI STUDY TO EVALUATE THE CYP3A4 INDUCTION POTENTIAL OF BELZUTIFAN IN HEALTHY PARTICIPANTS.
Favorite
P-089 - PERFORMANCE OF NLMIXR VS NONMEM FOR THE ESTIMATION OF PHARMACOMETRICS MODELS WITH DIFFERENT DEGREES OF NON-LINEARITY; AN AMGEN EXPERIENCE.
Favorite
P-095 - GINKGO: A SHINY APPLICATION FOR NON-COMPARTMENTAL ANALYSIS.
Favorite
P-097 - EXPLORATION THE POTENTIAL IMPACT OF BATCH-TO-BATCH VARIABILITY OF INHALATION POWDER DRUG PRODUCTS ON PHARMACOKINETIC BIOEQUIVALENCE STUDY POWER.
Favorite
P-098 - EXPLORING THE RELATIONSHIP BETWEEN THE IN VITRO PROPERTIES AND PHARMACOKINETICS PARAMETERS OF ADVAIR DISKUS.
Favorite
P-099 - EVALUATING NOVEL PILOT PHARMACOKINETIC BIOEQUIVALENCE STUDY FOR INHALATION POWDER DRUG PRODUCTS EXHIBITING BATCH-TO-BATCH DEVIATION.
Favorite
P-100 - POPULATION PHARMACOKINETICS MODELING FOR FLUTICASONE PROPIONATE AND SALMETEROL XINAFOATE INHALATION POWDER IN A BIOEQUIVALENCE STUDY.
Favorite
P-103 - APPLICATION OF MACHINE LEARNING FOR EXPOSURE-RESPONSE ANALYSIS WITH SURVIVAL ENDPOINT IN ONCOLOGY.
Favorite
P-106 - APPLICATION OF MACHINE LEARNING FOR EXPOSURE-RESPONSE RELATIONSHIP ANALYSIS OF BINARY ENDPOINTS IN ONCOLOGY.
Favorite
P-107 - EFFECTS OF H2-RECEPTOR ANTAGONISTS ON THE EXPOSURE OF DACOMITINIB.
Favorite
P-110 - LIMITED SAMPLING STRATEGY OF FEXOFENADINE PLASMA CONCENTRATIONS TO ESTIMATE CONSTITUTIVE P-GLYCOPROTEIN ACTIVITY IN HEALTHY ADULTS.
Favorite
P-114 - POPULATION-PK (POP-PK) AND EXPOSURE-RESPONSE (E-R) ANALYSES FOR BELZUTIFAN TO INFORM DOSING CONSIDERATIONS AND LABELING.
Favorite
P-115 - PHYSIOLOGICALLY BASED PHARMACOKINETIC (PBPK) MODELS MODEL TO INFORM THE RISKS ASSOCIATED WITH NATURAL MONOAMINE OXIDASE INHIBITORS.
Favorite
P-119 - PBPK MODELING TO ASSESS PHARMACOGENETIC IMPLICATIONS ON THE FLUOXETINE-CLOPIDOGREL DRUG-DRUG INTERACTION.
Favorite
P-120 -
WITHDRAWN
- ECULIZUMAB PK/PD MODELING AND SIMULATION FOR PERSONALIZED DOSE ADJUSTMENT IN BLEEDING PATIENTS WITH STEM CELL TRANSPLANT-ASSOCIATED THROMBOTIC MICROANGIOPATHY (TA-TMA).
Favorite
P-132 - EXENATIDE ONCE-WEEKLY (EQW) PHARMACOKINETICS AND HbA1c EXPOSURE RESPONSE ARE SIMILAR BETWEEN ADOLESCENT PATIENTS WITH TYPE 2 DIABETES MELLITUS (T2DM) AND ADULTS WITH T2DM.
Favorite
P-134 - LORLATINIB (LOR) POPULATION PHARMACOKINETIC (POPPK) MODEL WITH MECHANISTIC NONLINEAR CLEARANCE.
Favorite
P-135 - FEXOFENADINE CONCENTRATIONS TO ESTIMATE SYSTEMIC EXPOSURE AND P-GLYCOPROTEIN ACTIVITY USING A LIMITED SAMPLING STRATEGY WITH A POPULATION PHARMACOKINETIC APPROACH IN HEALTHY ADULTS.
Favorite
P-139 - A NOVEL DOUBLE-TRACER TECHNIQUE TO CHARACTERIZE ABSORPTION, DISTRIBUTION, METABOLISM, AND EXCRETION OF ORAL [
14
C]MITAPIVAT AND CONCOMITANT INTRAVENOUS MICRODOSE ADMINISTRATION OF [
13
C
6
]MITAPIVAT IN HUMANS.
Favorite
P-141 - A SURVEY OF EXPOSURE-RESPONSE ASSESSMENTS AND THE APPLICATION OF LONGITUDINAL MODELS IN US FOOD AND DRUG ADMINISTRATION REVIEWS OF NEW MOLECULAR ENTITIES APPROVED IN 2016–2021.
Favorite
P-143 -
WITHDRAWN
- A LONGITUDINAL MODEL-BASED META-ANALYSIS OF ABSOLUTE FVC IN IDIOPATHIC PULMONARY FIBROSIS.
Favorite
P-151 - IMPACT OF UDP-GLUCURONOSYL TRANSFERASE 1A1 (UGT1A1) POLYMORPHISMS ON THE PHARMACOKINETICS (PK) OF SACITUZUMAB GOVITECAN (SG).
Favorite
P-152 - POPULATION PHARMACOKINETICS OF GS-5718, AN ORAL INTERLEUKIN-1 RECEPTOR-ASSOCIATED KINASE 4 (IRAK4) INHIBITOR, IN HEALTHY SUBJECTS.
Favorite
P-154 - DERMAL CLEARANCE, ELIMINATION HALF-LIFE, AND APPARENT VOLUME OF DISTRIBUTION OF LIDOCAINE AND PRILOCAINE ARE INDEPENDENT OF THE DOSE DELIVERED DIRECTLY IN DERMIS USING A DERMAL INFUSION TECHNIQUE.
Favorite
P-155 - A PHYSIOLOGICALLY BASED PHARMACOKINETIC (PBPK) MODEL OF COBICISTAT (COBI) TO PREDICT PEDIATRIC EXPOSURE.
Favorite
P-156 - UPDATED PHYSIOLOGICAL BASED PHARMACOKINETIC MODELLING OF OSIMERTINIB FOR ASSESSMENT OF DRUG-DRUG INTERACTION WITH CYP1A2 AND CYP2C8 SUBSTRATES.
Favorite
P-161 - PHARMACOKINETICS (PK) OF SACITUZUMAB GOVITECAN (SG), A TROP-2-DIRECTED ANTIBODY-TOPOISOMERASE I INHIBITOR SN-38 DRUG-CONJUGATE, IN PATIENTS (PTS) WITH ADVANCED SOLID TUMORS.
Favorite
P-163 - USE OF POPULATION MODELING TO CHARACTERIZE THE PHARMACOKINETICS OF OXCARBAZEPINE AND ITS METABOLITE IN CHILDREN AND ADOLESCENTS WITH OBESITY.
Favorite
P-164 - INCREASING APPLICATION OF PEDIATRIC PBPK MODELS ACROSS ACADEMIC AND INDUSTRY ORGANISATIONS.
Favorite
P-174 - RANDOMIZED OPEN-LABEL STUDY TO ASSESS RELATIVE BIOAVAILABILITY OF DIFFERENT ORAL FORMULATIONS, THE EFFECT OF FOOD ON ABSORPTION AND ABSOLUTE BIOAVAILABILITY OF AZD9833 (CAMIZESTRANT) IN POST-MENOPAUSAL HEALTHY FEMALE VOLUNTEERS.
Favorite
P-175 - OPEN-LABEL STUDY TO EVALUATE THE EFFECT OF ITRACONAZOLE AND FLUCONAZOLE ON THE PHARMACOKINETICS OF VALEMETOSTAT TOSYLATE (VALEMETOSTAT, DS-3201b) IN HEALTHY PARTICIPANTS.
Favorite
P-183 - HOW MUCH MECHANISTIC DATA DO WE NEED? HOW A PRAGMATIC PBPK MODELING APPROACH CAN RESULT IN INACCURATE EXPOSURE PREDICTIONS FOR MEROPENEM IN PRETERM NEONATES WHILE ADEQUATE FOR OLDER CHILDREN.
Favorite
P-189 - THE FEASIBILITY OF USING POPULATION (POP) PHARMACOKINETICS (PK) BASED VIRTUAL CONTROL GROUP IN PHARMACOKINETIC STUDIES IN SUBJECTS WITH ORGAN (RENAL/HEPATIC) IMPAIRMENT (OI).
Favorite
P-195 - POPULATION PHARMACOKINETIC MODELING AND SIMULATION OF TQ-B3101 TO INFORM DOSING IN PEDIATRIC PATIENTS WITH ANAPLASTIC LARGE CELL LYMPHOMA.
Favorite
P-196 - POPULATION PHARMACOKINETICS (PK) AND PHARMACODYNAMICS (PD) OF ETRUMADENANT (AB928) IN HEALTHY VOLUNTEERS AND CANCER PATIENTS.
Favorite
P-197 - HANDLING TIME VARYING COVARIATES IN PHARMACOKINETIC MODELING OF MONOCLONAL ANTIBODIES IN INFANTS.
Favorite
P-207 - EVALUATION OF CONCENTRATION-QTC RELATIONSHIP OF BIIB095 IN A PHASE 1 SINGLE AND MULTIPLE ASCENDING DOSE STUDY.
Favorite
P-212 - POPULATION PHARMACOKINETICS OF SASANLIMAB IN PATIENTS WITH SOLID TUMORS: MODELING-BASED ANALYSIS OF DATA FROM THE FIRST-IN-PATIENT TRIAL.
Favorite
PT-002 - DEVELOPMENTAL PHARMACOKINETICS AND PHARMACOGENOMICS OF ISONIAZID IN PREDOMINANTLY LOW-BIRTH-WEIGHT OR PRETERM INFANTS WITH OR WITHOUT HIV EXPOSURE.
Favorite
PT-002 - DEVELOPMENTAL PHARMACOKINETICS AND PHARMACOGENOMICS OF ISONIAZID IN PREDOMINANTLY LOW-BIRTH-WEIGHT OR PRETERM INFANTS WITH OR WITHOUT HIV EXPOSURE.
Favorite
PT-004 - PHARMACOKINETIC AND PHARMACODYNAMIC ANALYSIS OF PRIMARY CLINICAL OUTCOMES IN TREATING DRUG-SENSITIVE TUBERCULOSIS WITH FOUR-MONTH HIGH-DOSE RIFAPENTINE WITH AND WITHOUT MOXIFLOXACIN (STUDY 31/A5349).
Favorite
PT-004 - PHARMACOKINETIC AND PHARMACODYNAMIC ANALYSIS OF PRIMARY CLINICAL OUTCOMES IN TREATING DRUG-SENSITIVE TUBERCULOSIS WITH FOUR-MONTH HIGH-DOSE RIFAPENTINE WITH AND WITHOUT MOXIFLOXACIN (STUDY 31/A5349).
Favorite
PT-019 - UNCOVERING THE DISPROPORTIONAL IMPACT OF CHRONIC KIDNEY DISEASE ON THE RENAL SECRETION OF DRUGS VIA ORGANIC ANION TRANSPORTERS (OAT) 1 AND 3.
Favorite
PT-019 - UNCOVERING THE DISPROPORTIONAL IMPACT OF CHRONIC KIDNEY DISEASE ON THE RENAL SECRETION OF DRUGS VIA ORGANIC ANION TRANSPORTERS (OAT) 1 AND 3.
Favorite
PW-005 - ESTIMATION OF IN VIVO FMO3 ONTOGENY BY MECHANISTIC POPULATION PHARMACOKINETIC MODELLING OF RISDIPLAM IN INFANTS, CHILDREN AND ADULTS WITH SPINAL MUSCULAR ATROPHY.
Favorite
PW-008 - INCORPORATION OF PLACENTAL TRANSPORT IN PHYSIOLOGICALLY-BASED PHARMACOKINETIC (PBPK) MODELS TO PREDICT METFORMIN (MET) UMBILICAL CORD CONCENTRATION (UCC) AT TERM IN PREGNANT WOMEN WITH GESTATIONAL DIABETES (GDM).
Favorite
PW-015 - POPULATION PHARMACOKINETICS OF INTRAVENOUS AND SUBCUTANEOUS IMMUNOGLOBULINS IN PATIENTS WITH PRIMARY IMMUNODEFICIENCIES.
Favorite
PW-016 - LONGITUDINAL MODELING OF EFFICACY RESPONSE IN PATIENTS WITH LUPUS NEPHRITIS (LN).
Favorite
E-002 - MIGALASTAT TISSUE DISTRIBUTION: EXTRAPOLATION FROM MICE TO HUMANS USING PHARMACOKINETIC MODELING AND COMPARISON WITH AGALSIDASE BETA TISSUE DISTRIBUTION IN MICE.
Favorite
LB-003 - DISEASE PROGRESSION MODEL TO PREDICT LONGITUDINAL MINI-MENTAL STATE EXAM (MMSE) TRAJECTORY IN ALZHEIMER’S DISEASE.
Favorite
LB-004 - BETWEEN-ASSAY VARIABILITY MIGHT EXPLAIN DIFFERENCES IN PROPOSED Z-ENDOXIFEN EFFICACY THRESHOLDS – EXPLORATORY ANALYSIS RESULTS OF THE CYP2D6 PERCENTAGE ACTIVITY ENDOXIFEN MODEL IN BREAST CANCER (CEPAM) CONSORTIUM DATABASE.
Favorite
LB-007 - GASTRIC EFFECTS USING PBPK MODELING WITH TELAGLENASTAT.
Favorite
LB-010 - A PHASE 1 CLINICAL STUDY OF THE SELECTIVE CARDIAC MYOSIN INHIBITOR AFICAMTEN IN HEALTHY CHINESE SUBJECTS.
Favorite
LB-011 - ENCOURAGING PHARMACOKINETIC (PK)/PHARMACODYNAMIC (PD) RESULTS OF SUBCUTANEOUS (SC) BLINATUMOMAB IN RELAPSED OR REFRACTORY (R/R) INDOLENT NON-HODGKIN’S LYMPHOMA (I-NHL) AND R/R ACUTE LYMPHOBLASTIC LEUKEMIA (ALL) PATIENTS (PTS) INDICATE THAT PATIENT CONVENIENT SC DOSING IS A VIABLE ALTERNATIVE TO CONTINUOUS INTRAVENOUS INFUSION (CIV) DOSING.
Favorite